Ms. Heather Medwick reports

CYTOPHAGE WELCOMES NEW CHAIRMAN THOMAS WELLNER AND ANNOUNCES GRANT OF OPTIONS AND RSUS

Cytophage Technologies Ltd. has appointed Thomas Wellner as the new chairman of the board subsequent to his election as a director at the annual and special meeting (ASM) of the shareholders on June 25, 2025. Mr. Wellner was selected by the board to stand for election and was appointed as board chairman based on his outstanding leadership experience in biotechnology and pharmaceutical companies, in-depth governance experience, and extensive global business network.

"I am honoured to be joining Cytophage's board of directors and grateful for the opportunity to serve as board chair at such a pivotal stage of the company's product advancements," said Mr. Wellner. "I am excited to work alongside my fellow board members and to leverage my experience to help Cytophage progress with making their cutting-edge phage technology a mainstream commercial solution for global animal and human health challenges."

Mr. Wellner is a highly experienced corporate executive with over three decades of global experience in biotechnology, pharmaceutical, and health care services companies. Following a successful 20-year global career with Eli Lilly, culminating as chief executive officer of Lilly Germany, Mr. Wellner led several health care organizations, LifeLabs/CML Healthcare and Therapure Biopharma. He recently retired as president and chief executive officer of Revera Inc., a leading global owner, operator and developer in the senior living/health care sector.

Mr. Wellner currently serves on the board of Andlauer Health Group, where he chairs the audit committee. He also currently serves on the board of the Ontario Teachers' Pension Plan and SE Health. He has previously served on the boards of FreshBooks, Novadaq Technologies, Cipher Pharmaceuticals, Diamedica and various Revera Inc. entities and has been an adviser to a variety of private equity, venture capital funds and family offices. He has his ICDD designation from the Rotman School of Business and has been a guest lecturer on international business and health care at Harvard, Rotman and INSEAD schools of business. He is also a published author.

Cytophage confirms the approval of all matters presented to the shareholders at the ASM. Information on the re-elected members of the board of directors can be found on the Cytophage website.

The company also announces that it issued incentive stock options on July 31, 2025, to purchase an aggregate of 170,000 common shares of the company at a price of 35 cents per common share to certain officers of the company. The stock options vest over 24 months from the date of issue and expire July 31, 2032.

In addition on July 31, 2025, the company issued 1,447,500 restricted stock units to officers, directors and consultants of the company; 1,247,500 RSUs to members of the board vest in one year and 200,000 RSUs to the officers vest over 36 months. Each RSU entitles the holder to receive one share of the company.

The stock options and RSUs were granted under Cytophage's equity incentive plan.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular- or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets, with an initial focus on animal health, which offers a fast track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO (World Health Organization) predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventive antibiotic use in animal production, including 27 European Union countries, the United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.